Day One Biopharmaceuticals Inc (NASDAQ: DAWN) kicked off on Friday, up 5.33% from the previous trading day, before settling in for the closing price of $6.76. Over the past 52 weeks, DAWN has traded in a range of $6.41-$18.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -41.12%. With a float of $74.28 million, this company’s outstanding shares have now reached $101.12 million.
Let’s determine the extent of company efficiency that accounts for 181 employees. In terms of profitability, gross margin is 95.89%, operating margin of -165.65%, and the pretax margin is -67.36%.
Day One Biopharmaceuticals Inc (DAWN) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Day One Biopharmaceuticals Inc is 26.71%, while institutional ownership is 83.56%. The most recent insider transaction that took place on Feb 18 ’25, was worth 52,278. In this transaction COO, CFO AND SECRETARY of this company sold 4,370 shares at a rate of $11.96, taking the stock ownership to the 252,638 shares. Before that another transaction happened on Feb 18 ’25, when Company’s GENERAL COUNSEL sold 4,646 for $11.96, making the entire transaction worth $55,580. This insider now owns 39,602 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -41.12% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Take a look at Day One Biopharmaceuticals Inc’s (DAWN) current performance indicators. Last quarter, stock had a quick ratio of 7.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.04, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Looking closely at Day One Biopharmaceuticals Inc (NASDAQ: DAWN), its last 5-days average volume was 1.48 million, which is a jump from its year-to-date volume of 1.19 million. As of the previous 9 days, the stock’s Stochastic %D was 35.67%. Additionally, its Average True Range was 0.59.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 8.82%, which indicates a significant decrease from 35.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.74% in the past 14 days, which was higher than the 61.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.54, while its 200-day Moving Average is $12.78. However, in the short run, Day One Biopharmaceuticals Inc’s stock first resistance to watch stands at $7.39. Second resistance stands at $7.65. The third major resistance level sits at $8.05. If the price goes on to break the first support level at $6.73, it is likely to go to the next support level at $6.33. Should the price break the second support level, the third support level stands at $6.07.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
The company with the Market Capitalisation of 721.68 million has total of 101,355K Shares Outstanding. Its annual sales at the moment are 131,160 K in contrast with the sum of -95,500 K annual income. Company’s last quarter sales were recorded 29,210 K and last quarter income was -65,710 K.
